Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Covalon TechnologiesCVALF -1.01%83 Debt-to-Equity is 0.06 as of Mar. 2026, which is 25% below its 10-year median of 0.08. GuruFocus rates CVALF with a GF Score™ of 83/100 and a GF Value™ of $1.54 (Fairly Valued). The stock has 2 warning signs investors should review. Among 706 Medical Devices & Instruments companies, Covalon Technologies ranks better than 77.76% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Covalon Technologies's Debt-to-Equity or its related term are showing as below:
CVALF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.08 Max: 2.49
Current: 0.06
During the past 13 years, the highest Debt-to-Equity Ratio of Covalon Technologies was 2.49. The lowest was 0.02. And the median was 0.08.
CVALF's Debt-to-Equity is ranked better than 77.76% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs CVALF: 0.06
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Covalon Technologies Debt-to-Equity Related Terms
Covalon Technologies Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Covalon Technologies's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVALF vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Covalon Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Covalon Technologies Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Covalon Technologies's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Covalon Technologies's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Covalon Technologies (CVALF) has a Debt-to-Equity of 0.06 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Covalon Technologies and its competitors. This is 25% below median its historical median of 0.08. Over the past decade, Covalon Technologies' Debt-to-Equity has ranged from 0.02 to 2.49. According to the industry distribution chart, Covalon Technologies ranks #157 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 22.2%.
Is Covalon Technologies' Debt-to-Equity too high?
Covalon Technologies' current Debt-to-Equity of 0.06 is 25% below median its 10-year median of 0.08. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 2.49. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Covalon Technologies' value of 0.06 is 73.3% below this industry median. Based on the distribution chart, Covalon Technologies ranks #157 out of 706 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Covalon Technologies has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Covalon Technologies' Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Covalon Technologies ranks #157 out of 706 companies for Debt-to-Equity. This places Covalon Technologies in the top 22% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Covalon Technologies' value of 0.06 is 73.3% below this benchmark. Historically, Covalon Technologies' own Debt-to-Equity has ranged from 0.02 to 2.49 over the past decade. While the company's 10-year median is 0.08 vs. the industry median of 0.23, Covalon Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Covalon Technologies's current Debt-to-Equity of 0.06 is 73.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Covalon Technologies and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Covalon Technologies's current Debt-to-Equity is 0.06, which is 25% below median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Covalon Technologies stock overvalued right now?
Based on GuruFocus' analysis, Covalon Technologies (CVALF) is currently considered Fairly Valued. The stock's GF Value™ is $1.54, compared to a current price of $1.48 — trading 4.2% below its estimated fair value. The current Debt-to-Equity is 0.06, which is 25% below median its 10-year median of 0.08 and 73.3% below the Medical Devices & Instruments industry median of 0.23. Covalon Technologies' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Covalon Technologies (CVALF), the current Debt-to-Equity is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Covalon Technologies (CVALF) Overvalued in 2026?
Based on GuruFocus' analysis, Covalon Technologies stock appears to be undervalued.
The current stock price of $1.48 is trading 4.2% below its estimated GF Value™ of $1.54.
GuruFocus considers Covalon Technologies to be Fairly Valued.
Key valuation signals for CVALF:
Debt-to-Equity: 0.06 (25% below median its 10-year median of 0.08)
GF Value™: $1.54 vs. price of $1.48 (4.2% below fair value)
Industry Position: 73.3% below the Medical Devices & Instruments median (#157 of 706)
No single metric tells the full story. See the CVALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.
83GF Score
Get the complete analysis for CVALF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVALF has been successfully added to your 
